Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than +70 active research sites across the globe. It is the second-largest clinical research site organization in the world. Its member companies have over 100 years of combined experience and have completed more than 7,000+ studies helping to evaluate thousands of new drugs and treatments in more than 140,000 patients. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.

hyperCORE and its partner members look to elevate the highly fragmented and inherently inefficient site model – something each member has already done on a singular level will now be achieved on a much larger scale. By combining their strengths and through further integration, the alliance is sure to turn some heads. Currently, the hyperCORE super network has more than +70 sites across 2 continents.

hyperCORE International is 100% committed in leading the charge in direct-to-patient clinical research. Also known as decentralized clinical trials (DCT), direct-to-patient research is in the best interest of the patients we serve as well as the entire clinical trial industry. Not only do these trials broaden accessibility, thereby increasing trial enrollment, but they also simplify the workload for trial teams. We aim to engage with industry and technology such that decentralized trials become more commonplace, and provide a win-win scenario for all involved.